Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Article in Cancer Medicine (October 2023)
The most recent citing publications are shown below. View all 109 publications that cite this research output on Dimensions.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
Article in The Lancet Haematology (October 2023)
A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma
Article in Cancers (September 2023)